🇺🇸 FDA
Pipeline program

TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE, TEMOZOLOMIDE, TEMOZOLOMIDE, TEMOZOLOMIDE, TEMOZOLOMIDE, LEE011, TEMOZOLOMIDE, TEMOZOLOMIDE

CLEE011Q12101

Phase 2 small_molecule active

Quick answer

TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE, TEMOZOLOMIDE, TEMOZOLOMIDE, TEMOZOLOMIDE, TEMOZOLOMIDE, LEE011, TEMOZOLOMIDE, TEMOZOLOMIDE for Relapsed or refractory neuroblastoma and other solid tumors (including medulloblastoma, high grade glioma, malignant rhabdoid tumors, and rhabdomyosarcoma) is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Ophthalmics Europe
Indication
Relapsed or refractory neuroblastoma and other solid tumors (including medulloblastoma, high grade glioma, malignant rhabdoid tumors, and rhabdomyosarcoma)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials